Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Prestige Consumer Healthcare ( (PBH) ) has provided an announcement.
On May 10, 2026, Prestige’s Australian subsidiaries agreed to acquire all shares of LaCorium Health group entities, a leader in Australian therapeutic skin care, from a group of sellers for about $150 million in cash, with closing expected in the second quarter of fiscal 2027 subject to customary conditions. LaCorium, which generated roughly $40 million in revenue in the twelve months to February 28, 2026 and holds leading market positions in Australian lip and foot care, is expected to add around $12 million of EBITDA post-integration, strengthening Prestige’s dermatological portfolio, geographic reach, and growth profile, while related indemnity and termination provisions underscore a structured risk-allocation approach for stakeholders.
On May 13, 2026, Prestige reported fiscal 2026 revenues of $1.09 billion, down 4.3% year over year, and diluted EPS of $3.91, with performance pressured by supply constraints in Clear Eyes and Middle East shipping disruptions but supported by strong free cash flow of $246.4 million and growth in brands such as Fleet, Dramamine, and Hydralyte. The company also outlined fiscal 2027 guidance calling for 1%–3% organic revenue growth, adjusted diluted EPS of $4.42–$4.51, and free cash flow of at least $250 million, signaling confidence that its acquisition strategy, including LaCorium and Breathe Right, and diversified brand portfolio will sustain earnings and cash generation despite a volatile consumer environment and ongoing eye-care supply normalization.
The most recent analyst rating on (PBH) stock is a Buy with a $65.00 price target. To see the full list of analyst forecasts on Prestige Consumer Healthcare stock, see the PBH Stock Forecast page.
Spark’s Take on PBH Stock
According to Spark, TipRanks’ AI Analyst, PBH is a Neutral.
The score is driven primarily by strong cash flow quality and solid recent profitability with improved leverage, reinforced by earnings-call guidance that maintained free cash flow targets and highlighted margin strength. These positives are partially offset by weak technicals (downtrend and bearish momentum), continued near-term revenue headwinds (supply constraints/category softness), and added leverage/execution risk from the Breathe Right acquisition.
To see Spark’s full report on PBH stock, click here.
More about Prestige Consumer Healthcare
Prestige Consumer Healthcare Inc. is a U.S.-based over-the-counter healthcare company focused on branded consumer products across categories such as gastrointestinal, eye and ear care, women’s health, cough and cold, and therapeutic skincare. Its portfolio includes brands like Fleet, Dramamine, Hydralyte, and Clear Eyes, and it has a significant international presence, particularly in Australia through subsidiaries such as Care Pharmaceuticals.
Average Trading Volume: 520,676
Technical Sentiment Signal: Sell
Current Market Cap: $2.39B
Learn more about PBH stock on TipRanks’ Stock Analysis page.